Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first approved in 2019 for adults ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
The drug "has proven to be a transformational treatment option for many patients with TRD by reducing depression symptoms in as little as 24 hours and reducing the time to relapse for patients who ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression. The drug made by Johnson & Johnson under the brand name Spravato passed final ...